Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H Kraus

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Neurology, Neurosurgery, and Psychiatry|November 19, 2004
Apolipoprotein E genotypes do not influence the age of onset in Huntington's diseaseC Saft, J E Andrich, N Brune, et al.
European Journal of Neurology|March 4, 1999
SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopaH Przuntek, B Conrad, J Dichgans, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 18, 2004
A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPAJ Marinus, M Visser, A M Stiggelbout, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinuedH Przuntek, D Welzel, E Blümner, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyH Przuntek, D Welzel, M Gerlach, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Neurology, Neurosurgery, and Psychiatry|November 19, 2004
Apolipoprotein E genotypes do not influence the age of onset in Huntington's diseaseC Saft, J E Andrich, N Brune, et al.
European Journal of Neurology|March 4, 1999
SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopaH Przuntek, B Conrad, J Dichgans, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 18, 2004
A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPAJ Marinus, M Visser, A M Stiggelbout, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinuedH Przuntek, D Welzel, E Blümner, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyH Przuntek, D Welzel, M Gerlach, et al.
Pageof 2